<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36030555</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Inhibition of MEK signaling prevents SARS-CoV2-induced lung damage and improves the survival of infected mice.</ArticleTitle><Pagination><StartPage>6097</StartPage><EndPage>6102</EndPage><MedlinePgn>6097-6102</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.28094</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) is the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Over 500 million confirmed cases of COVID-19 have been recorded, with six million deaths. Thus, reducing the COVID-19-related medical burden is an unmet need. Despite a vaccine that is successful in preventing COVID-19-caused death, effective medication to relieve COVID-19-associated symptoms and alleviate disease progression is still in high demand. In particular, one in three COVID-19 patients have signs of long COVID syndrome and are termed, long haulers. At present, there are no effective ways to treat long haulers. In this study, we determine the effectiveness of inhibiting mitogen-activated protein kinase (MEK) signaling in preventing SARS-CoV-2-induced lung damage in mice. We showed that phosphorylation of extracellular signal-regulated kinase, a marker for MEK activation, is high in SARS-CoV-2-infected lung tissues of mice and humans. We also showed that selumetinib, a specific inhibitor of the upstream MEK kinases, reduces cell proliferation, reduces lung damage following SARS-CoV-2 infection, and prolongs the survival of the infected mice. Selumetinib has been approved by the US Food and Drug Administration to treat cancer. Further analysis indicates that amphiregulin, an essential upstream molecule, was upregulated following SARS-CoV-2 infection. Our data suggest that MEK signaling activation represents a target for therapeutic intervention strategies against SARS-CoV-2-induced lung damage and that selumetinib may be repurposed to treat COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Jingwu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, The Wells Center for Pediatrics Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klemsz</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kacena</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandusky</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaplan</LastName><ForeName>Mark H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002529</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 DK106846</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI057459</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI045515</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066258">Amphiregulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048049">Extracellular Signal-Regulated MAP Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.25</RegistryNumber><NameOfSubstance UI="D020930">MAP Kinase Kinase Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.12.2</RegistryNumber><NameOfSubstance UI="D020929">Mitogen-Activated Protein Kinase Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D066258" MajorTopicYN="N">Amphiregulin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048049" MajorTopicYN="N">Extracellular Signal-Regulated MAP Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020930" MajorTopicYN="N">MAP Kinase Kinase Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020929" MajorTopicYN="N">Mitogen-Activated Protein Kinase Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ERK phosphorylation</Keyword><Keyword MajorTopicYN="N">Ki67</Keyword><Keyword MajorTopicYN="N">MEK</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">lung</Keyword><Keyword MajorTopicYN="N">mouse model</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>28</Day><Hour>17</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36030555</ArticleId><ArticleId IdType="mid">NIHMS1832771</ArticleId><ArticleId IdType="pmc">PMC9538266</ArticleId><ArticleId IdType="doi">10.1002/jmv.28094</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid&#x2010;19. N Engl J Med. 2020;383(18):1757&#x2010;1766.</Citation><ArticleIdList><ArticleId IdType="pubmed">32329974</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin DA, Gulick RM, Martinez FJ. Severe Covid&#x2010;19. N Engl J Med. 2020;383(25):2451&#x2010;2460.</Citation><ArticleIdList><ArticleId IdType="pubmed">32412710</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker AM, Brigham E, Connolly B, et al. Addressing the post&#x2010;acute sequelae of SARS&#x2010;CoV&#x2010;2 infection: a multidisciplinary model of care. Lancet Respir Med. 2021;9(11):1328&#x2010;1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8525917</ArticleId><ArticleId IdType="pubmed">34678213</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. Short&#x2010;term and long&#x2010;term rates of postacute sequelae of SARS&#x2010;CoV&#x2010;2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumann M, Dobbelstein M. Adenovirus&#x2010;induced extracellular signal&#x2010;regulated kinase phosphorylation during the late phase of infection enhances viral protein levels and virus progeny. Cancer Res. 2006;66(3):1282&#x2010;1288.</Citation><ArticleIdList><ArticleId IdType="pubmed">16452180</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade AA, Silva PN, Pereira AC, et al. The vaccinia virus&#x2010;stimulated mitogen&#x2010;activated protein kinase (MAPK) pathway is required for virus multiplication. Biochem J. 2004;381(pt 2):437&#x2010;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1133850</ArticleId><ArticleId IdType="pubmed">15025565</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrader T, Dudek SE, Schreiber A, Ehrhardt C, Planz O, Ludwig S. The clinically approved MEK inhibitor trametinib efficiently blocks influenza A virus propagation and cytokine expression. Antiviral Res. 2018;157:80&#x2010;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">29990517</ArticleId></ArticleIdList></Reference><Reference><Citation>Laure M, Hamza H, Koch&#x2010;Heier J, et al. Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK&#x2010;inhibitor, ATR&#x2010;002, in cell culture and in the mouse model. Antiviral Res. 2020;178:104806.</Citation><ArticleIdList><ArticleId IdType="pubmed">32304723</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber A, Viemann D, Sch&#xf6;ning J, et al. The MEK1/2&#x2010;inhibitor ATR&#x2010;002 efficiently blocks SARS&#x2010;CoV&#x2010;2 propagation and alleviates pro&#x2010;inflammatory cytokine/chemokine responses. Cell Mol Life Sci. 2022;79(1):65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8747446</ArticleId><ArticleId IdType="pubmed">35013790</ArticleId></ArticleIdList></Reference><Reference><Citation>Santry LA, Ingrao JC, Yu DL, et al. AAV vector distribution in the mouse respiratory tract following four different methods of administration. BMC Biotechnol. 2017;17(1):43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5433059</ArticleId><ArticleId IdType="pubmed">28506256</ArticleId></ArticleIdList></Reference><Reference><Citation>Awosanya OD, Dalloul CE, Blosser RJ, et al. Osteoclast&#x2010;mediated bone loss observed in a COVID&#x2010;19 mouse model. Bone. 2022;154:116227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8486589</ArticleId><ArticleId IdType="pubmed">34607050</ArticleId></ArticleIdList></Reference><Reference><Citation>Song R, Gu D, Zhang L, et al. Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer. Mol Carcinog. 2018;57(11):1608&#x2010;1615.</Citation><ArticleIdList><ArticleId IdType="pubmed">30074279</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Gu D, Lee SS, et al. Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer. Oncogene. 2016;35(50):6378&#x2010;6388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5093084</ArticleId><ArticleId IdType="pubmed">27132508</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitmarsh AJ, Davis RJ. A central control for cell growth. Nature. 2000;403(6767):255&#x2010;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">10659830</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler ES, Bailey AL, Kafai NM, et al. SARS&#x2010;CoV&#x2010;2 infection of human ACE2&#x2010;transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020;21(11):1327&#x2010;1335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578095</ArticleId><ArticleId IdType="pubmed">32839612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L, Deng W, Huang B, et al. The pathogenicity of SARS&#x2010;CoV&#x2010;2 in hACE2 transgenic mice. Nature. 2020;583(7818):830&#x2010;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">32380511</ArticleId></ArticleIdList></Reference><Reference><Citation>Oladunni FS, Park JG, Pino PA, et al. Lethality of SARS&#x2010;CoV&#x2010;2 infection in K18 human angiotensin&#x2010;converting enzyme 2 transgenic mice. Nat Commun. 2020;11(1):6122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7705712</ArticleId><ArticleId IdType="pubmed">33257679</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>